Januvia

Januvia

sitagliptin

Manufacturer:

Merck Sharp & Dohme

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Sitagliptin phosphate
Indications/Uses
Monotherapy: Adjunct to diet & exercise to improve glycemic control in patients w/ type 2 DM. Combination therapy: Type 2 DM to improve glycemic control in combination w/ metformin, sulfonylurea, metformin + sulfonylurea, PPARγ agonist (eg, thiazolidinedione), metformin + PPARγ agonist or insulin (w/ or w/o metformin) when diet & exercise plus the single agent do not provide adequate glycemic control.
Dosage/Direction for Use
Monotherapy or combination therapy w/ metformin, sulfonylurea, insulin (w/ or w/o metformin), PPARγ agonist, metformin + sulfonylurea or metformin + PPARγ agonist 100 mg daily. In combination therapy w/ sulfonylurea or insulin, lower dose of sulfonylurea or insulin should be considered.
Administration
May be taken with or without food.
Special Precautions
Not for use in type 1 DM or treatment of diabetic ketoacidosis, sulphonylurea- or insulin-induced hypoglycemia. Renal insufficiency. Pregnancy & lactation. Childn <18 yr. Elderly.
Adverse Reactions
Abdominal pain, nausea, vomiting, diarrhea, dyspepsia, flatulence, hypoglycemia, headache, upper resp tract infection.
MIMS Class
ATC Classification
A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Januvia FC tab 25 mg
Packing/Price
28's
Form
Januvia FC tab 50 mg
Packing/Price
28's
Form
Januvia FC tab 100 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in